CD274 and non-small cell lung carcinoma: Immunotherapy has been recognized worldwide in the treatment of NSCLC, the response rate in patients with high expression of PD-L1 can even reach about 30% and the median survival time has been extended to about 20 months (Mazieres et al., 2021).